ObsEva SA (OBSV)
(Delayed Data from NSDQ)
$13.89 USD
-0.12 (-0.86%)
Updated May 3, 2019 04:13 PM ET
After-Market: $13.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.89 USD
-0.12 (-0.86%)
Updated May 3, 2019 04:13 PM ET
After-Market: $13.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ObsEva SA (OBSV) delivered earnings and revenue surprises of 7.14% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy
by Zacks Equity Research
ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids
by Zacks Equity Research
ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.
ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids
by Zacks Equity Research
ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.
Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?
by Zacks Equity Research
Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.
Implied Volatility Surging for ObsEva (OBSV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.
ObsEva (OBSV) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
ObsEva (OBSV) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
How ObsEva (OBSV) Stock Stands Out in a Strong Industry
by Zacks Equity Research
ObsEva (OBSV) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Catabasis (CATB) Partners with UK-Based Charity for DMD Study
by Zacks Equity Research
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
ObsEva Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.
ObsEva Enters Oversold Territory
by Zacks Equity Research
ObsEva SA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
ObsEva SA (OBSV) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ObsEva SA (OBSV) delivered earnings and revenue surprises of 23.17% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ObsEva SA (OBSV) delivered earnings and revenue surprises of -37.93% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ObsEva Ends Recruitment in Second Uterine Fibroids Study
by Zacks Equity Research
ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.
ObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ObsEva SA (OBSV) delivered earnings and revenue surprises of -18.00% and -50.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
ObsEva SA (OBSV) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ObsEva SA (OBSV) delivered earnings and revenue surprises of 8.70% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
ObsEva Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.
ObsEva (OBSV) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in ObsEva SA (OBSV).
Can the Rally in ObsEva (OBSV) Shares Continue?
by Zacks Equity Research
ObsEva SA (OBSV) has been on the move lately as the stock has risen by 22.7% in the past four weeks, and it is currently trading well above its 20-Day SMA.
ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ObsEva SA (OBSV) delivered earnings and revenue surprises of 9.26% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
ObsEva SA (OBSV) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.
What Falling Estimates & Price Mean for ObsEva (OBSV)
by Zacks Equity Research
ObsEva SA (OBSV) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.